Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metis TechBio CoFRA:RO9 +7.99%17 Cash Ratio is 6.54 as of Dec. 2025, which is 5% below its 10-year median of 6.87. GuruFocus rates FRA:RO9 with a GF Score™ of 17/100. The stock has 1 warning sign investors should review. Among 1,379 Biotechnology companies, Metis TechBio Co ranks better than 69.98% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Metis TechBio Co Cash Ratio Related Terms
Metis TechBio Co Cash Ratio Historical Data
* Premium members only.
The historical data trend for Metis TechBio Co's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metis TechBio Co Cash Ratio Chart
Metis TechBio Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Cash Ratio
0.66
8.56
7.20
6.54
Metis TechBio Co Quarterly Data
Dec22
Dec23
Dec24
Sep25
Dec25
Cash Ratio
0.66
8.56
7.20
6.55
6.54
FRA:RO9 vs VRTX, REGN, RVMD: Cash Ratio Comparison
For the Biotechnology subindustry, Metis TechBio Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metis TechBio Co Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Metis TechBio Co's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Metis TechBio Co's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metis TechBio Co (FRA:RO9) has a Cash Ratio of 6.54 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Metis TechBio Co and its competitors. This is near median its historical median of 6.87. Over the past decade, Metis TechBio Co's Cash Ratio has ranged from 0.66 to 8.56. According to the industry distribution chart, Metis TechBio Co ranks #414 out of 1379 companies in the Biotechnology industry, placing it in the top 30%.
Is Metis TechBio Co's Cash Ratio too high?
Metis TechBio Co's current Cash Ratio of 6.54 is near median its 10-year median of 6.87. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 8.56. The Biotechnology industry median Cash Ratio is 2.93. Metis TechBio Co's value of 6.54 is 123.2% above this industry median. Based on the distribution chart, Metis TechBio Co ranks #414 out of 1379 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Metis TechBio Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Metis TechBio Co's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Metis TechBio Co ranks #414 out of 1379 companies for Cash Ratio. This puts Metis TechBio Co in the upper half of its industry. The industry median Cash Ratio is 2.93. Metis TechBio Co's value of 6.54 is 123.2% above this benchmark. Historically, Metis TechBio Co's own Cash Ratio has ranged from 0.66 to 8.56 over the past decade. While the company's 10-year median is 6.87 vs. the industry median of 2.93, Metis TechBio Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,379 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metis TechBio Co's current Cash Ratio of 6.54 is 123.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Metis TechBio Co and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metis TechBio Co's current Cash Ratio is 6.54, which is near median its own 10-year median of 6.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metis TechBio Co stock overvalued right now?
Metis TechBio Co (FRA:RO9) has a current Cash Ratio of 6.54. The current Cash Ratio is 6.54, which is near median its 10-year median of 6.87 and 123.2% above the Biotechnology industry median of 2.93. Metis TechBio Co's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Metis TechBio Co (FRA:RO9), the current Cash Ratio is 6.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Metis TechBio Co Ltd is an investment holding company. The company and its subsidiaries are principally engaged in AI-empowered nanomaterial innovation for the delivery and application of active agents across all carbon-based life forms. Its technology platform, NanoForge, comprises a set of integrated tools, including a lipid library, AI models, an AI agent (METiS), quantum chemistry and molecular dynamics simulations, and high-throughput screening platforms. The company has developed three solution platforms (AiTEM, AiLNP, and AiRNA) designed to simulate, predict, and interpret nanoscale interactions, enabling the rational design, optimization, and validation of nanomaterials and their associated payloads.
17GF Score
Get the complete analysis for FRA:RO9
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RO9 has been successfully added to your 
